Developer Platform Unkey has written about rebuilding its entire API authentication service from the ground up, moving from ...

This weekly recap brings those stories together in one place. No overload, no noise. Read on to see what shaped the threat ...

Oui! Oui! It’s time to break out the baguettes. Sandfall and Kepler Interactive’s French action adventure game Clair Obscur: Expedition 33 staked claim on the Game of the Year prize at the 12th Game ...

At MAI (Microsoft AI), we don’t just build AI tools, we care about how real people interact with them. So as 2025 wraps up, we’ve gone headfirst into a mountain of de-identified data, searching for ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Jim Mickle, who wrote and showran Netlfix's 'Sweet Tooth' series, is directing the adaptation of the classic anime. By Borys Kit Senior Film Writer The actor, who is already shooting Street Fighter ...

Exact agreed to be bought out by Abbott Labs for $105 per share. The buyout is at a hefty premium to the share price at the start of the week, but still well below Exact's 2021 highs. Shareholders ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...